3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline is an intermediate in the preparation of Nilotinib, which is is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. This drug was developed by Novartis and is sold under the trade name Tasigna.
Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. 
Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations. 
 G. Zhang, et al, Bioorg. Med. Chem. Lett., 2009, 19, pp6691-6695.
 M.A.Seeliger, etal, Cancer Res., 2009, 69(6), pp2384-2392.
UN 2811 6.1/PG III
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email firstname.lastname@example.org.